KYMR insider buying and SEC filings, explained
Kymera Therapeutics, Inc. · CIK 1815442
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$198.6M
Planned sales (10b5-1)
$271.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 30,000 shares at about $113.80 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 4% to 666,568 shares. | SEC filing Filed Oct 1, 2026, 5:20 PM ET |
| Sep 4, 2026 | Sale | Brian Adams (Chief Legal Officer) sold 6,371 shares at about $116.83 ($744K). Holdings down 11% to 50,254 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 4, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 50,000 shares at $119.00 ($6.0M), marked as a 10b5-1 plan trade. Holdings down 7% to 666,568 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Noah Goodman (Chief Business Officer) sold 3,389 shares at $114.29 ($387K), marked as a 10b5-1 plan trade. Holdings down 7% to 47,179 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 80,000 shares at about $115.30 ($9.2M), marked as a 10b5-1 plan trade. Holdings down 11% to 666,568 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Bruce N. Jacobs (CFO) sold 77,109 shares at about $114.97 ($8.9M), marked as a 10b5-1 plan trade. Holdings down 24% to 244,883 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 29, 2026 | Planned (10b5-1) Amended filing | Bruce Booth (Director) sold 76,650 shares indirectly at about $108.05 ($8.3M), marked as a 10b5-1 plan trade. Indirect holdings down 14% to 462,856 shares. This amends a filing from Jun 30. | SEC filing Filed Jul 2, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 513,245 shares indirectly between Jun 26 and Jun 29 at about $110.01 ($56.5M), marked as a 10b5-1 plan trade. Indirect holdings down 52% to 466,077 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26, 2026 | Sale | Mark N. Lampert (Director and Officer) sold 1,630,658 shares directly and indirectly at $106.50 ($173.7M). Direct holdings down 87% to 240,123 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 9 other reporting owners. | SEC filing Filed Jun 26, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 285,684 shares indirectly at about $121.86 ($34.8M), marked as a 10b5-1 plan trade. Indirect holdings down 35% to 529,718 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Noah Goodman (Chief Business Officer) sold 5,000 shares at about $114.00 ($570K), marked as a 10b5-1 plan trade. Holdings down 9% to 50,195 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 23–25, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 398,765 shares indirectly between Jun 23 and Jun 25 at about $110.31 ($44.0M), marked as a 10b5-1 plan trade. Indirect holdings down 41% to 564,668 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 31,798 shares indirectly at about $103.75 ($3.3M), marked as a 10b5-1 plan trade. Indirect holdings down 5% to 613,762 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Noah Goodman (Chief Business Officer) sold 2,500 shares at $99.00 ($248K), marked as a 10b5-1 plan trade. Holdings down 5% to 50,195 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 17–22, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 478,198 shares directly and indirectly between Jun 17 and Jun 22 at about $94.72 ($45.3M), marked as a 10b5-1 plan trade. Direct holdings down 100% to 0 shares. | SEC filing Filed Jun 22, 2026 |
| May 26–27, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 17,184 shares between May 26 and May 27 at about $79.92 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 28% to 44,018 shares. | SEC filing Filed May 27, 2026 |
| May 11, 2026 | Planned (10b5-1) | Elena Ridloff (Director) sold 3,000 shares at $87.00 ($261K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 11, 2026 |
| Apr 29, 2026 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 30,000 shares at about $81.18 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 4% to 666,195 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 6,000 shares directly and indirectly at about $89.96 ($540K), marked as a 10b5-1 plan trade. Direct holdings down 100% to 0 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 300 shares at $90.00 ($27K), marked as a 10b5-1 plan trade. Holdings down <1% to 61,202 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 14–15, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 9,494 shares directly and indirectly between Apr 14 and Apr 15 at about $90.01 ($855K), marked as a 10b5-1 plan trade. Direct holdings down 100% to 0 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Noah Goodman (Chief Business Officer) sold 1,347 shares at $90.00 ($121K), marked as a 10b5-1 plan trade. Holdings down 3% to 50,195 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14–15, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 6,551 shares between Apr 14 and Apr 15 at about $90.00 ($590K), marked as a 10b5-1 plan trade. Holdings down 10% to 61,202 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 9–10, 2026 | Planned (10b5-1) | Noah Goodman (Chief Business Officer) sold 10,264 shares between Apr 9 and Apr 10 at about $87.47 ($898K), marked as a 10b5-1 plan trade. Holdings down 17% to 51,542 shares. | SEC filing Filed Apr 10, 2026 |
| Mar 31–Apr 1, 2026 | Planned (10b5-1) | Elena Ridloff (Director) sold 12,000 shares between Mar 31 and Apr 1 at about $85.39 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 31–Apr 1, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 22,240 shares between Mar 31 and Apr 1 at about $85.43 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 27% to 61,202 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 23–25, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 115,977 shares between Mar 23 and Mar 25 at about $78.02 ($9.0M), marked as a 10b5-1 plan trade. Holdings down 65% to 61,202 shares. | SEC filing Filed Mar 25, 2026 |
| Mar 20, 2026 | Planned (10b5-1) | Pamela Esposito (Director) sold 2,500 shares at about $79.15 ($198K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 20, 2026 |
| Mar 11, 2026 | Planned (10b5-1) | Jeremy G Chadwick (President / COO) sold 25,758 shares at about $83.30 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 27% to 68,052 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Bruce Booth (Director) sold 81,866 shares indirectly at about $90.13 ($7.4M), marked as a 10b5-1 plan trade. Indirect holdings down 11% to 675,341 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2–4, 2026 | Sale | Jeremy G Chadwick (President / COO) sold 5,958 shares between Mar 2 and Mar 4 at about $86.54 ($516K). Holdings down 7% to 73,810 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2–4, 2026 | Sale | Jared Gollob (Chief Medical Officer) sold 10,508 shares between Mar 2 and Mar 4 at about $87.24 ($917K). Holdings down 8% to 117,134 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2–4, 2026 | Sale | Bruce N. Jacobs (CFO) sold 12,471 shares between Mar 2 and Mar 4 at about $87.50 ($1.1M). Holdings down 5% to 232,588 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 30,000 shares at about $90.26 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 4% to 666,195 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 20, 2026 | Planned (10b5-1) | Pamela Esposito (Director) sold 2,500 shares at about $87.31 ($218K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Feb 20, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Pamela Esposito (Director) sold 5,500 shares at about $67.91 ($374K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 30,000 shares at about $78.06 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 4% to 663,077 shares. | SEC filing Filed Dec 31, 2025 |
| Dec 17, 2025 | Planned (10b5-1) | Pamela Esposito (Director) sold 27,563 shares at about $82.16 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 10–12, 2025 | Sale | Bruce Booth (Director) sold 236,588 shares indirectly between Dec 10, 2025 and Dec 12, 2025 at about $91.72 ($21.7M). Indirect holdings down 26% to 685,393 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 12, 2025 |
| Dec 11, 2025 | Other purchase | Julian Baker (Director and 10% owner) bought 2,005,813 Common Stock indirectly at $86.00 ($172.5M) in a public offering. Indirect holdings up 34% to 7,955,916 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 5 other reporting owners. | SEC filing Filed Dec 11, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Jeffrey W. Albers (Director) sold 5,000 shares at about $89.76 ($449K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 8, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Nello Mainolfi (CEO and Director) sold 100,000 shares at $89.17 ($8.9M), marked as a 10b5-1 plan trade. Holdings down 13% to 660,482 shares. | SEC filing Filed Dec 8, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Jared Gollob (Chief Medical Officer) sold 49,307 shares at about $88.66 ($4.4M), marked as a 10b5-1 plan trade. Holdings down 31% to 109,992 shares. | SEC filing Filed Dec 8, 2025 |
48 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow KYMR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.